These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
144 related articles for article (PubMed ID: 35798015)
1. Cabozantinib plus atezolizumab in advanced hepatocellular carcinoma and the role of adjuvant antiviral therapy. Ji F; Nguyen MH Lancet Oncol; 2022 Aug; 23(8):962-963. PubMed ID: 35798015 [No Abstract] [Full Text] [Related]
2. Cabozantinib plus atezolizumab for the treatment of advanced hepatocellular carcinoma: shedding light on the preclinical rationale and clinical trials. Cammarota A; Zanuso V; D'Alessio A; Pressiani T; Personeni N; Rimassa L Expert Opin Investig Drugs; 2022 Apr; 31(4):401-413. PubMed ID: 35072565 [TBL] [Abstract][Full Text] [Related]
3. Cabozantinib in combination with atezolizumab versus sorafenib in treatment-naive advanced hepatocellular carcinoma: COSMIC-312 Phase III study design. Kelley RK; W Oliver J; Hazra S; Benzaghou F; Yau T; Cheng AL; Rimassa L Future Oncol; 2020 Jul; 16(21):1525-1536. PubMed ID: 32491932 [TBL] [Abstract][Full Text] [Related]
4. Cabozantinib: An evolving therapy for hepatocellular carcinoma. El-Khoueiry AB; Hanna DL; Llovet J; Kelley RK Cancer Treat Rev; 2021 Jul; 98():102221. PubMed ID: 34029957 [TBL] [Abstract][Full Text] [Related]
5. Cost-Effectiveness of Cabozantinib in the Second-Line Treatment of Advanced Hepatocellular Carcinoma. Soto-Perez-de-Celis E; Aguiar PN; Cordón ML; Chavarri-Guerra Y; Lopes GL J Natl Compr Canc Netw; 2019 Jun; 17(6):669-675. PubMed ID: 31200357 [TBL] [Abstract][Full Text] [Related]
6. Atezolizumab plus bevacizumab for advanced, unresectable hepatocellular carcinoma. Tsilimigras DI; Moris D J BUON; 2021; 26(2):637. PubMed ID: 34077021 [No Abstract] [Full Text] [Related]
7. Optimizing Survival and the Changing Landscape of Targeted Therapy for Intermediate and Advanced Hepatocellular Carcinoma: A Systematic Review. Lim H; Ramjeesingh R; Liu D; Tam VC; Knox JJ; Card PB; Meyers BM J Natl Cancer Inst; 2021 Feb; 113(2):123-136. PubMed ID: 32898239 [TBL] [Abstract][Full Text] [Related]
8. Current Role of Atezolizumab Plus Bevacizumab Therapy in the Sequential Treatment of Unresectable Hepatocellular Carcinoma. Komatsu S; Yano Y; Fujishima Y; Ishida J; Kido M; Kuramitsu K; Yamamoto A; Goto T; Yanagimoto H; Toyama H; Ueda Y; Kodama Y; Fukumoto T Anticancer Res; 2022 Mar; 42(3):1403-1412. PubMed ID: 35220233 [TBL] [Abstract][Full Text] [Related]
9. Systemic Therapy for Hepatocellular Carcinoma: Advances and Hopes. Zhang CH; Li M; Lin YP; Gao Q Curr Gene Ther; 2020; 20(2):84-99. PubMed ID: 32600231 [TBL] [Abstract][Full Text] [Related]
10. Cabozantinib: A Review in Advanced Hepatocellular Carcinoma. Deeks ED Target Oncol; 2019 Feb; 14(1):107-113. PubMed ID: 30767164 [TBL] [Abstract][Full Text] [Related]
15. AGA Clinical Practice Guideline on Systemic Therapy for Hepatocellular Carcinoma. Su GL; Altayar O; O'Shea R; Shah R; Estfan B; Wenzell C; Sultan S; Falck-Ytter Y Gastroenterology; 2022 Mar; 162(3):920-934. PubMed ID: 35210014 [TBL] [Abstract][Full Text] [Related]
16. Cabozantinib as a second-line treatment option in hepatocellular carcinoma. D'Angelo A; Sobhani N; Bagby S; Casadei-Gardini A; Roviello G Expert Rev Clin Pharmacol; 2020 Jun; 13(6):623-629. PubMed ID: 32394749 [TBL] [Abstract][Full Text] [Related]
17. Cabozantinib in hepatocellular carcinoma: results of a phase 2 placebo-controlled randomized discontinuation study. Kelley RK; Verslype C; Cohn AL; Yang TS; Su WC; Burris H; Braiteh F; Vogelzang N; Spira A; Foster P; Lee Y; Van Cutsem E Ann Oncol; 2017 Mar; 28(3):528-534. PubMed ID: 28426123 [TBL] [Abstract][Full Text] [Related]
18. Cost-effectiveness of Atezolizumab Plus Bevacizumab vs Sorafenib as First-Line Treatment of Unresectable Hepatocellular Carcinoma. Su D; Wu B; Shi L JAMA Netw Open; 2021 Feb; 4(2):e210037. PubMed ID: 33625508 [TBL] [Abstract][Full Text] [Related]
19. Atezolizumab with or without bevacizumab in unresectable hepatocellular carcinoma (GO30140): an open-label, multicentre, phase 1b study. Lee MS; Ryoo BY; Hsu CH; Numata K; Stein S; Verret W; Hack SP; Spahn J; Liu B; Abdullah H; Wang Y; He AR; Lee KH; Lancet Oncol; 2020 Jun; 21(6):808-820. PubMed ID: 32502443 [TBL] [Abstract][Full Text] [Related]
20. Hypothyroidism in patients with hepatocellular carcinoma receiving cabozantinib: an unassessed issue. Di Nunno V; Frega G; Gatto L; Brandi G; Massari F Future Oncol; 2019 Feb; 15(6):563-565. PubMed ID: 30648889 [No Abstract] [Full Text] [Related] [Next] [New Search]